| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40,407 |
32,361 |
$2.84M |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
14,970 |
13,847 |
$681K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
14,028 |
13,017 |
$564K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
4,165 |
4,002 |
$448K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,277 |
4,065 |
$417K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
4,036 |
3,855 |
$395K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,696 |
3,430 |
$362K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,450 |
3,109 |
$297K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,852 |
2,671 |
$276K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,516 |
7,241 |
$239K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
6,311 |
5,794 |
$231K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
10,714 |
9,712 |
$166K |
| 94010 |
|
4,041 |
3,845 |
$103K |
| 99050 |
|
4,225 |
3,686 |
$68K |
| 85018 |
|
21,025 |
18,862 |
$61K |
| 85014 |
|
21,022 |
18,861 |
$61K |
| 96127 |
|
7,836 |
7,253 |
$56K |
| 80061 |
Lipid panel |
2,693 |
2,603 |
$46K |
| 99188 |
|
2,491 |
2,355 |
$42K |
| 69210 |
|
888 |
868 |
$37K |
| 86328 |
|
702 |
594 |
$34K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,256 |
2,828 |
$32K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
208 |
188 |
$28K |
| 81002 |
|
9,035 |
8,281 |
$25K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
138 |
138 |
$23K |
| 97802 |
|
9,097 |
8,479 |
$22K |
| 92551 |
|
7,592 |
7,086 |
$22K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
181 |
173 |
$19K |
| 94060 |
|
301 |
292 |
$15K |
| 99406 |
|
3,870 |
3,544 |
$15K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
8,378 |
7,734 |
$13K |
| 99173 |
|
7,894 |
7,309 |
$11K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
673 |
470 |
$11K |
| 94760 |
|
3,691 |
3,405 |
$9K |
| 82962 |
|
2,941 |
2,843 |
$9K |
| 0001A |
|
205 |
203 |
$8K |
| 96161 |
|
2,523 |
2,212 |
$8K |
| 96160 |
|
5,071 |
4,720 |
$8K |
| 0002A |
|
162 |
159 |
$6K |
| 94664 |
|
1,044 |
957 |
$6K |
| 99401 |
|
316 |
268 |
$5K |
| 99429 |
|
575 |
356 |
$4K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
114 |
114 |
$3K |
| 90651 |
|
2,160 |
2,044 |
$3K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
17 |
17 |
$3K |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
831 |
790 |
$2K |
| 36410 |
|
183 |
160 |
$1K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
78 |
71 |
$1K |
| 86756 |
|
100 |
87 |
$1K |
| 90620 |
|
3,232 |
3,034 |
$1K |
| 82947 |
|
196 |
193 |
$880.04 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
16 |
16 |
$632.00 |
| 91300 |
|
122 |
118 |
$572.38 |
| 0071A |
|
14 |
14 |
$560.14 |
| 71046 |
Radiologic examination, chest; 2 views |
17 |
17 |
$459.64 |
| 36416 |
|
14,578 |
12,436 |
$446.30 |
| 90686 |
|
3,362 |
3,167 |
$395.11 |
| 5250F |
|
1,340 |
1,275 |
$384.00 |
| 99072 |
|
1,471 |
1,214 |
$300.59 |
| 90716 |
|
1,141 |
1,093 |
$258.60 |
| 90715 |
|
893 |
871 |
$250.70 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
121 |
110 |
$192.80 |
| 90707 |
|
1,094 |
1,044 |
$145.96 |
| 90734 |
|
1,751 |
1,644 |
$128.38 |
| 90713 |
|
2,967 |
2,705 |
$127.88 |
| 80305 |
|
50 |
16 |
$122.70 |
| 36415 |
Collection of venous blood by venipuncture |
30 |
30 |
$28.80 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
98 |
92 |
$12.84 |
| 90633 |
|
1,411 |
1,345 |
$0.00 |
| 90670 |
|
2,921 |
2,665 |
$0.00 |
| 90648 |
|
2,874 |
2,621 |
$0.00 |
| 90685 |
|
563 |
544 |
$0.00 |
| 90700 |
|
3,595 |
3,309 |
$0.00 |
| G8496 |
All quality actions for the applicable measures in the preventive care measures group have been performed for this patient |
87 |
87 |
$0.00 |
| 90680 |
|
1,806 |
1,614 |
$0.00 |
| 90744 |
|
1,530 |
1,342 |
$0.00 |
| 91307 |
|
49 |
44 |
$0.00 |